Tatiana Takiishi, Hannelie Korf, Tom L. Van Belle, Sofie Robert, Fabio A. Grieco, Silvia Caluwaerts, Letizia Galleri, Isabella Spagnuolo, Lothar Steidler, Karolien Van Huynegem, Pieter Demetter, Clive Wasserfall, Mark A. Atkinson, Francesco Dotta, Pieter Rottiers, Conny Gysemans, Chantal Mathieu
CT stably reverts autoimmune diabetes in NOD mice.
Newly diagnosed diabetic NOD mice were treated as indicated, and glycemia was monitored until 14 weeks after treatment initiation. (A) Percentage of mice that remained diabetic after treatment. † indicates dead or moribund mice. (B) Individual blood glucose levels of newly diagnosed diabetic NOD mice treated with anti-CD3 monotherapy (left panel) or anti-CD3 and LL-PINS+hIL10 CT (right panel). Open symbols, hyperglycemic mice; filled symbols, normoglycemic mice at week 14. (C) Newly diagnosed diabetic NOD mice were stratified based on initial blood glucose level less than (gray symbols) or greater than (open symbols) 350 mg/dl. Shown is the percentage of mice that remained diabetic upon treatment with anti-CD3 monotherapy (left panel) or anti-CD3 and LL-PINS+hIL10 CT (right panel). In all panels, statistical significance between groups was determined by Mantel-Cox log-rank test; *P < 0.05, **P < 0.01.